UK Government Responses on Myalgic Encephalomyelitis (ME/CFS) – January 2026 Summary

Overview

This document compiles UK Parliamentary written questions and official government responses from January 2026 relating to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). It focuses on NHS service provision, care for severe and very severe ME/CFS, research funding, policy development, and implementation of NICE guidelines.

Key Points

1. NHS Services and Care Provision

• Responsibility for commissioning ME/CFS services sits with local Integrated Care Boards (ICBs), based on local population needs.
• The Government’s Final Delivery Plan on ME/CFS (published July 2025) includes actions intended to benefit all people with ME/CFS, regardless of severity.
• Specific attention is being given to people with severe and very severe ME/CFS, including exploration of whether a nationally prescribed specialist service should be established.
• Discussions between the Department of Health and Social Care (DHSC) and NHS England are ongoing to progress this work.
• The NHS 10‑Year Health Plan aims to shift more care into community settings through multidisciplinary neighbourhood health teams, improving support for people with long‑term conditions such as ME/CFS.

2. Professional Education and Awareness

• DHSC and NHS England have developed a dedicated ME/CFS e‑learning programme for healthcare professionals.
• All three training modules are now available via the NHS Learning Hub, with the goal of improving diagnosis, management, and patient outcomes.

3. Research and Funding

• DHSC holds overall responsibility for delivering the ME/CFS Final Delivery Plan.
• Research funding is provided mainly through:
  • National Institute for Health and Care Research (NIHR) – later‑stage and applied clinical research.
  • Medical Research Council (MRC) – aetiology and early‑stage translational research.
• Since 2020, the MRC has invested over £4.65 million in ME/CFS research.
• UK Research and Innovation (UKRI) supports collaboration between government‑funded bodies and private‑sector researchers.
• Projects such as DecodeME and LOCOME (Long COVID and ME diagnostics stratification) are actively informing the research landscape.
• The Government does not maintain disease‑specific research strategies but supports targeted initiatives where needed, such as priority‑setting partnerships.

4. Severe ME/CFS and Patient Safety

• Patient safety risks for people with severe and very severe ME/CFS, including risks such as malnutrition, were considered during development of the Final Delivery Plan.
• Engagement took place with clinicians, patient groups, and other stakeholders.
• An action within the plan specifically addresses the potential need for specialised services for very severe ME/CFS.

5. NICE Guidelines and Consistency

• NICE guidelines are evidence‑based and expected to be fully taken into account by healthcare professionals and ICB commissioners.
• NHS England monitors adherence to NICE guidance through statutory oversight frameworks, performance assessments, and clinical governance requirements.
• The Final Delivery Plan aims to improve consistency in diagnosis, access to specialist care, professional attitudes, and overall quality of life for people with ME/CFS.

6. Related Parliamentary Information

• Data on antidepressant prescribing does not distinguish clinical indications; therefore, it is not possible to identify prescriptions specifically for ME/CFS.
• The Government has stated it is keen to reflect emerging research findings in future health policy for ME/CFS and related post‑viral conditions, including Long COVID.

Summary
In January 2026, the UK Government reaffirmed its commitment to improving outcomes for people with ME/CFS through the Final Delivery Plan. Key priorities include better community‑based NHS services, targeted consideration for severe and very severe cases, improved clinician education, sustained research funding, and consistent application of NICE guidelines. Work is ongoing to strengthen specialist provision and ensure that emerging scientific evidence informs future policy.